Clinical Study

Ea3132- Phase II Randomized Trial Of Radiotherapy With Or Without Cisplatin For Surgically Resected Squamous Cell Carcinoma Of The Head And Neck (Scchn) With Tp53 Sequencing

Posted Date: Oct 26, 2020

  • Investigator: Trisha Wise-Draper
  • Specialties: Cancer, Head and Neck Cancer, Oncology
  • Type of Study: Drug

The purpose of this study is to evaluate the disease-free survival (DFS) of patients with stage III-IV squamous cell carcinoma of the head and neck (SCCHN) and disruptive p53 mutations after primary surgical resection followed by postoperative radiotherapy (PORT) alone or PORT with concurrent cisplatin


To Be Eligible: Must Have Pathologically Proven Diagnosis Of Squamous Cell Carcinoma, Ecog 0-1, Total Resection Of Tumor, Adequate Organ Function, No Previous Radiation To The Head And Neck, No Recurrent Disease, No Intercurrent Illness That Interferes With Protocol Therapy


Scchn, Head And Neck Cancer

For More Information:

Uc Cancer Center

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.